Washington Capital Management Inc. Sells 1,500 Shares of Solventum Corporation $SOLV

Washington Capital Management Inc. reduced its holdings in shares of Solventum Corporation (NYSE:SOLV) by 16.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,500 shares of the company’s stock after selling 1,500 shares during the quarter. Washington Capital Management Inc.’s holdings in Solventum were worth $569,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Rossby Financial LCC bought a new stake in shares of Solventum during the 1st quarter worth $25,000. Strengthening Families & Communities LLC raised its position in Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after purchasing an additional 260 shares during the last quarter. Hara Capital LLC bought a new position in Solventum in the first quarter valued at about $38,000. Smartleaf Asset Management LLC raised its position in Solventum by 193.4% in the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after purchasing an additional 352 shares during the last quarter. Finally, Costello Asset Management INC bought a new position in Solventum in the first quarter valued at about $42,000.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wells Fargo & Company increased their target price on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. KeyCorp assumed coverage on Solventum in a research report on Friday, June 6th. They issued a “sector weight” rating for the company. Piper Sandler reiterated an “overweight” rating and issued a $94.00 target price (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Jefferies Financial Group started coverage on Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $85.44.

Solventum Trading Up 1.4%

NYSE SOLV opened at $71.43 on Monday. The business has a 50 day simple moving average of $72.84 and a 200 day simple moving average of $72.23. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The stock has a market capitalization of $12.39 billion, a P/E ratio of 33.07, a P/E/G ratio of 2.90 and a beta of 0.53. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. During the same quarter last year, the firm posted $1.56 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.